Featured Research

from universities, journals, and other organizations

Clinical trial participation alone may not be associated with improved outcomes for childhood cancer patients

Date:
March 1, 2010
Source:
JAMA and Archives Journals
Summary:
Children with the most common childhood cancer did not experience improved outcomes from participating in a clinical trial between 1997 and 2005. Researchers studied 322 patients with newly diagnosed acute lymphoblastic leukemia (a cancer involving the white blood cells), approximately half of whom participated in one of several available clinical trial protocols for the disease.

Children with the most common childhood cancer did not experience improved outcomes from participating in a clinical trial between 1997 and 2005.

Carl Koschmann, M.D., and colleagues at the University of Washington and Seattle Children's Hospital studied 322 patients with newly diagnosed acute lymphoblastic leukemia (a cancer involving the white blood cells), approximately half of whom participated in one of several available clinical trial protocols for the disease.

Overall, 79 percent of the patients survived five years without recurrence of their leukemia, with no significant difference between study participants and non-participants (80 percent vs. 77 percent). "Clinical trial participation does not, by itself, lead to improved outcome for pediatric patients with acute lymphoblastic leukemia in the current era," the authors conclude. "Discussions about participation in a clinical trial should focus on improvement of future therapy, not the direct benefit of the research participant."

"Considerable evidence indicates that clinical trials are associated with substantial benefits as measured by both public health and economic gains," writes Steven Joffe, M.D., M.P.H., of the Dana-Farber Cancer Institute, Boston, in an accompanying editorial. "In the modern era, five-year survival rates for children with acute lymphoblastic leukemia are 80 percent to 90 percent. It is likely that these remarkable outcomes owe much not only to the legacy of treatment insights derived from past trials, but also to the happy side effect of improved quality attributable to the existence of a cooperative clinical trials program and infrastructure in the settings in which most children with cancer receive their care."

The research appears in Archives of Pediatrics & Adolescent Medicine.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Carl Koschmann; Blythe Thomson; Douglas S. Hawkins. No Evidence of a Trial Effect in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia. Arch Pediatr Adolesc Med, 2010; 164 (3): 214-217 [link]
  2. Steven Joffe. Framing the Benefits of Cancer Clinical Trials. Arch Pediatr Adolesc Med, 2010; 164 (3): 293-294 [link]

Cite This Page:

JAMA and Archives Journals. "Clinical trial participation alone may not be associated with improved outcomes for childhood cancer patients." ScienceDaily. ScienceDaily, 1 March 2010. <www.sciencedaily.com/releases/2010/03/100301171056.htm>.
JAMA and Archives Journals. (2010, March 1). Clinical trial participation alone may not be associated with improved outcomes for childhood cancer patients. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/03/100301171056.htm
JAMA and Archives Journals. "Clinical trial participation alone may not be associated with improved outcomes for childhood cancer patients." ScienceDaily. www.sciencedaily.com/releases/2010/03/100301171056.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins